ATE135220T1 - Verwendung von 1-alpha,24(r)-dihydroxy-22(e)- dehydrovitamin-d3 zur herstellung eines arzneimittels zur behandlung der osteoporose - Google Patents

Verwendung von 1-alpha,24(r)-dihydroxy-22(e)- dehydrovitamin-d3 zur herstellung eines arzneimittels zur behandlung der osteoporose

Info

Publication number
ATE135220T1
ATE135220T1 AT93303249T AT93303249T ATE135220T1 AT E135220 T1 ATE135220 T1 AT E135220T1 AT 93303249 T AT93303249 T AT 93303249T AT 93303249 T AT93303249 T AT 93303249T AT E135220 T1 ATE135220 T1 AT E135220T1
Authority
AT
Austria
Prior art keywords
dihydroxy
alpha
osteoporosis
dehydrovitamin
producing
Prior art date
Application number
AT93303249T
Other languages
English (en)
Inventor
Hector Floyd Deluca
Heinrich Konstantine Schnoes
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Application granted granted Critical
Publication of ATE135220T1 publication Critical patent/ATE135220T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT93303249T 1992-04-24 1993-04-26 Verwendung von 1-alpha,24(r)-dihydroxy-22(e)- dehydrovitamin-d3 zur herstellung eines arzneimittels zur behandlung der osteoporose ATE135220T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87337492A 1992-04-24 1992-04-24

Publications (1)

Publication Number Publication Date
ATE135220T1 true ATE135220T1 (de) 1996-03-15

Family

ID=25361517

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93303249T ATE135220T1 (de) 1992-04-24 1993-04-26 Verwendung von 1-alpha,24(r)-dihydroxy-22(e)- dehydrovitamin-d3 zur herstellung eines arzneimittels zur behandlung der osteoporose

Country Status (10)

Country Link
US (1) US5395830A (de)
EP (1) EP0567352B1 (de)
JP (1) JP2769960B2 (de)
KR (1) KR940005275A (de)
AT (1) ATE135220T1 (de)
AU (1) AU666529B2 (de)
CA (1) CA2094424C (de)
DE (1) DE69301750T2 (de)
IL (1) IL105475A (de)
NZ (1) NZ247406A (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009958A1 (en) * 1991-01-08 2004-01-15 Bone Care International, Inc. Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2
US5661140A (en) * 1994-11-21 1997-08-26 Wisconsin Alumni Research Foundation 18-nor-vitamin D compounds
US5716946A (en) * 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment
KR100474517B1 (ko) * 1997-10-27 2005-07-21 삼성전자주식회사 엘씨디패널절단장치
US6479474B2 (en) 1999-07-08 2002-11-12 Wisconsin Alumni Research Foundation Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis
AU7706800A (en) * 1999-09-24 2001-04-30 Quing Non Yng-Wong Delivery of small doses of ingestible treatments
US7888338B2 (en) * 2004-12-06 2011-02-15 K.U. Leuven Research & Development 7-(2-cyclohexylidene-ethylidene)-spiro[4.5]decanes
DK1993375T3 (en) * 2006-03-10 2017-07-17 Dsm Ip Assets Bv Hitherto UNKNOWN USE OF NUTRACEUTIC COMPOSITIONS IN ANIMAL FEED.
SG2014006324A (en) * 2009-01-27 2014-03-28 Berg Llc Vitamin d3 and analogs thereof for alleviating side effects associated with chemotherapy
CN102655869B (zh) 2009-08-14 2016-08-10 博格有限责任公司 用于治疗脱发的维生素d3及其类似物
HK1222819A1 (zh) 2013-05-29 2017-07-14 博格有限责任公司 使用维生素d预防或减轻化疗诱发的脱发

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833622A (en) * 1969-03-17 1974-09-03 Upjohn Co Crystalline 25-hydroxycholecalciferol hydrate and structurally related compounds
US3901928A (en) * 1973-01-10 1975-08-26 Robert Henry Hesse 1' ,3' -dihydroxy steroid-5-enes method of preparing same and their use for preparing 1' -hydroxy-25-hydrogen vitamin d compounds
US4260549A (en) * 1979-05-21 1981-04-07 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4267117A (en) * 1978-06-19 1981-05-12 The Upjohn Company Compounds and process
US4255596A (en) * 1980-02-25 1981-03-10 Gulf Research & Development Company Preparation of ethylene glycol from ethylene
JPS6089422A (ja) * 1983-10-24 1985-05-20 Kureha Chem Ind Co Ltd 抗骨粗鬆症剤
US4719204A (en) * 1984-03-05 1988-01-12 Wisconsin Alumni Research Foundation Fowl bone mineralization with 28-NOR 1α-hydroxyvitamin D2 analogs
US4588716A (en) * 1984-05-04 1986-05-13 Wisconsin Alumni Research Foundation Method for treating metabolic bone disease in mammals
US4588528A (en) * 1984-05-31 1986-05-13 Wisconsin Alumni Research Foundation 1,24-dihydroxy-Δ22 -vitamin D3 and process for preparing same
US4822609A (en) * 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
US5001118A (en) * 1986-12-29 1991-03-19 Kureha Kagaku Kogyo Kabushiki Kaisha Method for preventing senescence and increasing bone mass
US4997824A (en) * 1987-07-22 1991-03-05 Teva Pharmaceutical Industries Ltd. Combination of cholecalciferol derivatives for the treatment of renal bone disease
US5104864A (en) * 1988-08-02 1992-04-14 Bone Care International, Inc. Method for treating and preventing loss of bone mass
US5053401A (en) * 1989-02-28 1991-10-01 Chugai Seiyaku Kabushiki Kaisha Osteogenesis promotion with use of vitamin d derivatives

Also Published As

Publication number Publication date
DE69301750D1 (de) 1996-04-18
NZ247406A (en) 1999-05-28
US5395830A (en) 1995-03-07
AU3689193A (en) 1993-10-28
IL105475A (en) 1997-06-10
IL105475A0 (en) 1993-08-18
JPH0624992A (ja) 1994-02-01
EP0567352A1 (de) 1993-10-27
CA2094424C (en) 2001-01-02
AU666529B2 (en) 1996-02-15
EP0567352B1 (de) 1996-03-13
KR940005275A (ko) 1994-03-21
DE69301750T2 (de) 1996-07-25
CA2094424A1 (en) 1993-10-25
JP2769960B2 (ja) 1998-06-25

Similar Documents

Publication Publication Date Title
DE69435330D1 (de) Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen
DE69428130D1 (de) Verwendung von bcl-2 zur herstellung von arzneimitteln zur therapeutischen behandlung und verhinderung von krankheiten
ATE141505T1 (de) Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht
DE69913665D1 (de) Verwendung von follistatin zur herstellung eines arzneimittels zur behandlung von muskuläre krankheiten
DE3856594D1 (de) Mittel zur behandlung der alzheimer-krankheit
DE3585607D1 (de) Verwendung von paroxetine zur herstellung eines arzneimittel zur behandlung von obesitaet.
DE3484055D1 (de) Verwendung von ubidecarenon zur herstellung eines medikaments zur behandlung von durch radiotherapie hervorgerufenen geschwueren.
DE3785740D1 (de) Verwendung von carboxamid-verbindungen zur herstellung eines arzneimittels zur behandlung der hyperlipaemie.
ATE135220T1 (de) Verwendung von 1-alpha,24(r)-dihydroxy-22(e)- dehydrovitamin-d3 zur herstellung eines arzneimittels zur behandlung der osteoporose
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
WO1998025573A3 (en) The use of celastrol to treat alzheimer's disease
ATE222491T1 (de) Melatonin-derivate zur verwendung in der behandlung von schlafstörungen
DE3854121D1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
DE69432626D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Desynchronisierungs-Erkankungen
DE69026511D1 (de) Verwendung von gibberellinen zur herstellung eines arzneimittels zur behandlung von prostatitis
DE3768150D1 (de) Verwendung eines 1,3-oxazolidin-2-on-derivates zur herstellung eines arzneimittels zur behandlung von ischaemie.
DE3675115D1 (de) Verwendung von verbindungen zur herstellung eines medikaments fuer die behandlung von grauem star.
DE3686097D1 (de) Verwendung von dopamin-agonisten zur herstellung eines arzneimittels zur behandlung von psychostimulant-sucht.
DE68916777D1 (de) Verwendung von TNF zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis.
DE69433687D1 (de) Die verwendung von wachstumshormon zur herstellung eines medikaments zur behandlung der ischämischen hirnschädigung und demenz
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
DE69424415D1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
ATE147267T1 (de) Verwendung von 24,25-dihydroxyvitamin-d3 zur herstellung eines arzneimittel zur behandlung der rachitis
DE69632117D1 (de) Verwendung von 8,9-Dehydroestron zur Herstellung eines Arzneimittels zur Behandlung von durch freie Radikale verursachte Krankheiten
DE3777709D1 (de) Verwendung von 3'azido-3'deoxythymidin zur herstellung eines arzneimittels zur behandlung von gardiasis.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties